Abstract The authors present the
The Marfan syndrome and the cardiovascular surgeon
Abstract The authors present the current status of surgery for the cardiovascular manifestations of the Marfan syndrome. In addition, a brief review of current Marfan genetic research is presented. Data on all Marfan patients undergoing aortic root replacement at the Johns Hopkins Hospital (September 1976-June 1995) were analyzed. Survival and event-free curves were calculated and risk factors for early and late death were determined by univariate and multivariate analysis. Two hundred twelve Marfan patients underwent aortic root replacement using composite graft (202), homograft (8) or valve-sparing procedures (2) . One hundred eighty-five patients underwent elective repair with no 30-day mortality. Twenty-seven patients underwent urgent surgery, primarily for acute dissection; two patients with aortic rupture died in the operating room. Actuarial survival of the 212 patients was 88% at 5 years, 78% at 10 years and 71% at 14 years. By multivariate analysis, only poor NYHA class, male gender and urgent surgery emerged as significant independent predictors of early or late mortality. Histologic examination of excised Marfan aortic leaflets by immunofluorescent staining for fibrillin showed fragmentation of elastin-associated microfibrils. These studies suggest cautious use of valve-sparing procedures in Marfan patients. Over the last 5 years significant progress has been made in identifying mutant genes that code for defective fibrillin microfibrils in Marfan patients. Attempts are underway to develop animal models of Marfan disease for study of possible gene therapy. [1] . In recent years, many articles from your continent and ours have reported hospital mortality rates for the Bentall composite graft procedure of 5% or less with excellent long-term results. Despite these outstanding results, we seem to be at a major transition point in the surgical management of Marfan aneurysm of the ascending aorta. This is because of the recent introduction of valve-sparing procedures for patients with ascending aorta aneurysms. These new procedures may well eliminate serious potential problems related to prosthetic valves in composite grafts; on the other hand, the proponents of these valve-sparing procedures recommend cautious application in Marfan patients, who may have a propensity for continuing annulo-aortic ectasia.
In this presentation we would like to give you: 1) an updated summary of the surgical results at The Johns Hopkins Hospital for patients with Marfan aneurysm of the ascending aorta, 2) a brief overview of the current role of the valvesparing procedures for Marfan aneurysm and 3) a survey of recent developments in the field of Marfan genetics.
tive technique has evolved from the original Bentall technique and has been described in detail in several recent publications [11 -13] . For the last several years we have used the St. Jude composite graft without wrapping the graft with aneurysm wall and without Cabrol interposition grafts. During the early years of this surgical series we preferred direct anastomosis of the coronary ostia to the Dacron graft: currently, we routinely anastomose coronary osteal buttons to the Dacron graft. In the two patients undergoing a valve-sparing procedure, the Yacoub remodeling technique [ 19] , was used in one patient and the Dawd relmplantation technique [5] was used m the other.
Standard hypothermic (28°-30°C) cardiopulmonary bypass techniques were used. Myocardial protection used to consist of simple antegrade administration of crystalloid potassium cardioplegia solution and maintenance of myocardial hypothermla by continuous topical 4 °C sahne solution given at a rate of 100 ml/min. During the past 12 months cold retrograde blood perfusion has been utilized. Of 212 root replacement patients, 14 (6.6%) required hypothermic circulatory arrest for partial resection of the aortic arch or to facilitate anastomosis of the composite graft to the proximal arch.
Statistical methods
Survival and event-free curves were calculated with the KaplanMeier method. Univarlate analysis was performed using the MantelCox method and the multivariate analysis by the Cox proportional hazards methods. Survival data are presented with standard error of the estimate. Statistical computations were made using BMDP statistical software package 1.
Methods for histological evaluation of excised marfan aortic leaflets
Between May 1994 and February 1995, specimens of aortic valve and aortic wall were obtained from 14 patients operated on for aortic root aneurysm or dissection. Fibrllhn staining employing indirect immunofluorescence was used to identify differences in fibrillin content and architecture between pauents with (n = 8) and without (n = 6) the Marfan syndrome. Quantity, homogeneity and fragmentation of fibrillin in the specimens was graded by a pathologist blinded to the identity of the patient source.
Patients and methods

Patient selection
Two hundred twelve marfan patients from the Johns Hopkins Hospital underwent aortic root replacement for aneurysm of the ascendmg aorta between September 1976 and June 1995. Two hundred two of these patients underwent a composite graft replacement using the Bentall technique or its modification. Eight patients (two adults and six children) received homograft roots as their primary procedure. mainly to avoid anticoagulatlon associated with mechanical prostheses. Two recent patients had aortic root replacement using the valve-sparing techmque. All patient data were entered into a computerized patient registry; late follow-up data were obtained from chnical records and direct contact with pattents and their primary physicians.
Operative technique
Two hundred two patients underwent aortic root replacement with a composite graft as first described by Bentall [1] . Our current opera-
Results
Preoperative patient characteristics
One hundred fifty-six of the 212 patients were male (73 %) and 56 (26%) were female. The mean patient age was 32.4 years (range 4.4-73.3 years).
Forty-two of the 212 patients ( 19.8 %) had dis section of the ascending aorta (Table 1) . Twenty were acute dissections, while 22 were chronic. The mean diameter of the ascending aorta in the total group of 212 patients was 6.8 cm (range 4.5-10 cm). The mean diameter of the 42 ascending aortas with dissection was 7.6 cm; 12 patients had dissection in aortas that measured 6.5 cm or less. Operative results Table 2 presents the 30-day mortality for the 212 patients undergoing aortic root replacement (30-day mortality is comparable to hospital mortality). There were no deaths among 185 patients undergoing elective aortic root replacement for Marfan aneurysm of the ascending aorta.
The two early deaths in this series occurred among the 27 patients who underwent urgent or emergent operation. Both of these patients arrived moribund in the operating room with ruptured aortas and pericardial tamponade; both died in the operating room. Of the 27 patients undergoing urgent repair, 20 had acute dissection of the ascending aorta ( Table 1) . The remaining seven patients had impending dissection or low cardiac output due to severe left ventricular dysfunction. Thirty-five of the 212 root replacement patients (16.5 %) also had mitral valve procedures (Table 3 ). Twenty-four had concomitant repair with an annuloplasty ring, eight had concomitant mitral replacement, and three had mitral replacement at a separate procedure. There were no early deaths among these 35 patients. There have been 20 late deaths among 210 hospital survivors (9.5%). Table 4A depicts the causes of late death as well as non-fatal late complications. There were five late deaths among the first 11 patients; these patients were operated on between 1976 and 1979. Over the last 16 years there have been 15 late deaths among 199 hospital survivors (7.5%). Figure 1 depicts actuarial survival of the entire group of 212 patients; survival was 88% at 5 years, 78% at 10 years and 71% and 14 years.
Multiple patient-and procedure-related variables were screened by univariate and subsequent multivariate analysis as potential risk factors for early or late death (Table 5), These variables included preoperative NYHA functional class, gender~ urgent/elective surgery, age, presence of aortic dissection, mitral valve operation, use of hypothermic circulatory arrest, previous aortic root surgery and era of operation. In a multivariate analysis, only NYHA class, male gender, and urgent surgery emerged as signif- Table 4 A footnote ** Patient had remodeling type of valve-sparing procedure icant independent predictors of early or late death. Age, preoperative dissection and mitral valve operation were not significant independent predictors of early or late death. Noteworthy complications among the 210 survivors are listed in Table 4 B. Endocarditis was the most common late complication after root replacement. Eight of the 210 hospital survivors (3.8%) developed late endocarditis. Freedom from endocarditis in the series was 96%, 91%, and 91% at 5, 10, and 14 years, respectively (Fig. 2) . Figure 3 presents actuarial freedom from thromboembolism in 200 composite graft patients after hospital discharge. This complication occurred in five patients (Table 4B). In one patient, thrombus developed on a BjorkShiley valve 10 years after operation. This patient underwent successful composite re-replacement with a St. Jude Medical prosthesis. Embolic episodes were recorded in four other composite graft patients, all of whom recovered completely. Three embolic events were in the setting of inadequate coagulation. Thus, the rate of thromboembolic events in patients discharged with a composite graft was 0.63 events per 100 patient years (5 events over 792 patient-years). One patient, who had the Yacoub valve-sparing procedure, sustained a minor transient embolic episode on the 1st postoperative day. 
Postoperative Year
Actuarial freedom from problems w~th the unoperated aorta Three patients died of late aortic rupture (Table 4 A). Fifteen patients required a subsequent surgical procedure on the unoperated aorta (12 for dissection and three for dilatation); 11 are long-term survivors. Fig. 4 presents actuarial freedom from reoperation or rupture of the unoperated aorta.
Discussion
This report and several others [2, 4, 15, 16] indicate that Bentall's original operation has proven to be a safe and durable procedure for patients with Marfan aneurysm of the ascending aorta. In all recent series the 30-day mortality for aortic root replacement is below 5%. Late survival after composite graft repair of ascending aorta aneurysm has also been gratifying. The major question at this time is the role of valve-sparing procedures for Marfan patients with aortic root aneurysm. These procedures were introduced by Yacoub [19] and David [5] and have obvious advantages, such as avoidance of lifetime anticoagulation, virtual elimination of thromboembolism and reduced risk of endocarditis. These considerations make the valve-sparing procedures attractive but, because of potential ongoing annular dilatation and aortic valvular degeneration in patients with the Marfan syndrome, caution is needed regarding the use of these valve-sparing procedures.
In this series, thromboembolism occurred at a relatively low incidence; only 5 of 200 (2.5%) composite graft patients sustained a thromboembolic event. In three instances the events occurred within the 1st few days or weeks after surgery. All were related to inadequate anticoagulation and complete recovery was achieved. The thromboembolic rate of 0.63 per 100 patient-years is slightly more than half of that of the isolated Bjork-Shiley or St. Jude valves [3] . Patients with composite grafts therefore appear to be at less risk of thromboembolism than those with isolated prosthetic aortic valves, possibly due to the exclusion of valve sutures and pledgets from the circulation in the composite graft group. Interestingly, even one of our two patients that had a valve-sparing procedure sustained a minor embolic event on the 1st postoperative day.
Endocarditis has been a significant complication of the composite graft. In the three patients in our series with endocarditis treated with homograft root replacement, endocarditis was eradicated. It is worth noting that endocarditis has not occurred in the last 5.5 years of this series (the last 80 patients). This may be due to better patient compliance in the use of parenteral antibiotics for dental work. It has been our recommendation that all patients with a composite graft utilize parenteral antibiotic coverage for dental procedures rather than oral antibiotics as recommended by the American Heart Association.
For reasons previously stated, valve-sparing procedures have gained wide acceptance in the last few years; Table 6 presents data on this procedure from four surgical groups with significant operative experience. Contraindications for valve-sparing procedures include aortic leaflets that are over-stretched or bicuspid and an aortic annulus that exceeds 40 mm in diameter. Duran and associates published a cautionary case report [9] of reoperation 14 months after a David re-implantation procedure. The valve cusps were thin and pliable at the first operation but were thick- Recent histologic studies at our institution by three of the co-authors (C. S., G. A. and K, F.) revealed a surprising amount of structural deterioration of aortic leaflets excised from Marfan patients at the time of composite graft replacement [8] . The histologic structure of a non-Marfan aortic leaflet and aortic leaflets from two Marfan patients is depicted in Fig. 5 . Immunofluorescent fibrillin staining technique demonstrates that the elastin-associated microfibrils in the two Marfan leaflets are moderately (Fig. 6 B) and markedly (Fig. 6C) fragmented. The fibrillin that makes up much of the microfibrils is a large glycoprotein, essential to the structural integrity of many types of connective tissue including aortic wall and leaflets. From the histologic images in Fig. 6 , it is also apparent that fibrillin content is diminished in Marfan leaflets. These recent studies showing diminished fibrillin and microfibril degeneration in excised Marfan aortic leaflets suggest that caution be used in the routine use of valve-sparing procedures for Marfan patients. It is our current feeling that the operation of choice for Marfan patients remains the modified Bentall procedure, though valve-sparing operations may be preferable in selected patients. Clearly, the outlook for Marfan patients undergoing elective surgical repair of ascending aorta aneurysms is now gratifying. Accompanying the improved surgical results have been spectacular developments in understanding the genetics of the Marfan syndrome. It has been known for years that Marfan disease is transmitted by autosomal dominant inheritance. It has also been known for some time that the connective tissue of Marfan patients contains defective fibrillin. This not only explains the abnormal findings in Fig. 5 , but also the structural weakness in the suspensory ligament of the lens, tendons, ligaments and aortic wall. Defective fibrillin can account for the striking changes in elastin shown in scanning electron micrograph (SEM) studies published 10 years ago by Perejda, et al. [8] (Fig. 6 ). These studies show that in a cross-section of normal aortic elastin, there are longitudinal parallel laminae with numerous perpendicular interlamellar fibers. However, in the Marfan aorta there is a marked reduction in the interlamellar connecting fibers with, in some patients, a Swiss cheese-like appearance of the elastin fibers.
In 1990, a Finnish research team lead by Katariina Kainulainen [ 14] demonstrated that the fibrillin gene is located on the long arm of chromosome 15. In 1991, Dietz and associates at Johns Hopkins [6] reported their discovery of the first mutation in the fibrillin gene. Figure 7 is adapted from that publication and shows a missense (point) mutation with transversion of guanine to cytosine at nucleotide 716 (Fig. 7A ). This mutation results in the substitution of the amino acid proline for arginine in the fibrillin monomer (Fig. 7B) . A subsequent publication by Dietz and associates [7] described seven additional mutations in the fibrillin gene in Marfan patients. Figure 8 shows a precisely pleated 42 amino acid polypeptide that makes up most of the fibrillin monomer. It is known that fibrillin has a high affinity for calcium and that the calcium binding by this pleated polypeptide depends on the six cysteine (C) amino acids with disulfide linkages as indicated by the bold lines. As noted in Fig. 8 , four of the new mutations occurred at a cysteine location, resulting in substitution of other amino acids for the critical cysteine. Calcium binding by the pleated domain not only depends on having the six precisely spaced cysteine residues, but also on precise placement of the amino acids designated as D, N and Y. In addition to the seven mutations depicted here, Dietz and associates have recently reported seven other mutations in this structure [17] . It follows that if normal fibrillin function depends on calcium-binding properties of the pleated domains and this property is severely altered by mutant changes, then strength of connective tissue in the aortic wall will be reduced.
The inability of fibroblast cells from Marfan patients to deposit fibrillin effectively into the extra cellular matrix is Fig. 9 , originally published by Godfrey et al. [ 10] . This figure shows immunofluorescent stained microfibrils of fibrillin in fibroblast cultures from a family with the Marfan syndrome. The fibroblast cultures from the unaffected father and daughter are shown in the upper left and lower right panels, respectively. Cultures from the affected mother and two affected sons are shown in the upper right and lower two panels on the left. These panels show that there is deficient fibrillin deposition by Marfan fibroblasts. At the present time, the search for additional mutant fibrillin alleles is proceeding at a rapid pace in many laboratories throughout the world. To date, 55 mutations of the fibrillin gene have been reported in the literature; 30 of these are from Dietz' laboratory. To date, the significance of identification of these 55 fibrillin mutations has enabled the diagnosis of Marfan disease in some patients before they become symptomatic, and even prenatal diagnosis has been achieved in a few patients. Dietz and associates and others have attempted to develop a mouse model for the Marfan s y n d r o m e over the last 2 years. They have injected Marfan human genes into single mouse cells (fertilized eggs). It is their hope that a mouse model will be the first step toward gene therapy for the Marfan syndrome. Our ultimate goal is to eliminate Marfan disease completely, however, at this time, this seems virtually impossible. Successful gene therapy would probably entail replacement of the mutant gene in somatic cells of the tissue at risk, such as the fibroblast and smooth muscle cell of the aortic media soon after conception. Since each offspring of an affected patient carries only a 50% risk of inheriting the mutant gene, an accurate method to determine that the embryo carries the mutation would be needed. It is likely that the ethical issues raised by such genetic manipulation are considerably more complex than those of somatic gene therapy at a post-natal stage.
Still, it is possible that, in the next century, genetic therapy may ameliorate the Marfan syndrome with all of its dire consequences. In the meantime, the use of beta blockers [20] and other pharmacological intervention may retard the aortic dilatation in these patients. W h e n the ascending aortic aneurysm exceeds 5 -6 cm, there are valuable surgical procedures that can be performed with low operative risk that may, in turn, provide near normal life expectancy.
